Ray Dingledine

No ORCID on file · 4 papers in corpus
review 2026
Annual review of pharmacology and toxicology ·doi:10.1146/annurev-pharmtox-062124-043519

We explore three emerging molecular pathways driving neuroinflammation in chronic and acute brain diseases: the EP2 receptor for prostaglandin E2, the CCR2 receptor for chemokine CCL2, and JAK/STAT signaling. Inflammation is now recognized …

lab-animal 2020
Journal of medicinal chemistry ·doi:10.1021/acs.jmedchem.9b01218

Activation of prostanoid EP2 receptor exacerbates neuroinflammatory and neurodegenerative pathology in central nervous system diseases such as epilepsy, Alzheimer's disease, and cerebral aneurysms. A selective and brain-permeable EP2 antago…

lab-animal 2018
Molecular pharmaceutics ·doi:10.1021/acs.molpharmaceut.8b00764

The prostaglandin E2 receptor, EP2, plays an important role in physiology and in a variety of pathological conditions. Studies indicate that EP2 is pro-inflammatory in chronic peripheral and central nervous system disease and cancer models.…

review 2013
Trends in pharmacological sciences ·doi:10.1016/j.tips.2013.05.003

Modulation of a specific prostanoid synthase or receptor provides therapeutic alternatives to nonsteroidal anti-inflammatory drugs (NSAIDs) for treating pathological conditions governed by cyclooxygenase-2 (COX-2 or PTGS2). Among the COX-2 …